Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancerXin Xu, Zhiyong Sun, Qiang Liu, Yao Zhang, Lei Shen, Chenpeng Zhang, Haiping Lin, Bin Hu, Ling Rong, Haiyan Chen, Xiaohang Wang, Xiaojing Zhao, Yong-Rui Bai, Qing Ye, Xiumei Ma
7 March 2024
Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysisKatsuhiko Nara, Satoru Taguchi, Sebastiano Buti, Taketo Kawai, Yukari Uemura, Takehito Yamamoto, Haruki Kume, Tappei Takada
7 March 2024
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromesAmin H Nassar, Talal El Zarif, Ahmed Bilal Khalid, Serena Rahme, Caiwei Zhong, Lucia Kwak, Marita Salame, Elias Bou Farhat, Dory Freeman, Edward El-Am, Arjun Ravishankar, Bachar Ahmad, Frank Aboubakar Nana, David Kaldas, Abdul Rafeh NaqashSee the full list of authors
5 March 2024
Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitisHironori Bando, Masaaki Yamamoto, Shin Urai, Yuma Motomura, Yuriko Sasaki, Yuka Ohmachi, Masaki Kobatake, Yasutaka Tsujimoto, Yuka Oi-Yo, Masaki Suzuki, Naoki Yamamoto, Michiko Takahashi, Hidenori Fukuoka, Genzo Iguchi, Wataru Ogawa
28 February 2024
Cardiovascular toxicities associated with bispecific T-cell engager therapyAhmed Sayed, Malak Munir, Sanam M Ghazi, Mussammat Ferdousi, Satyam Krishan, Adnan Shaaban, Alma Habib, Onaopepo Kola-Kehinde, Patrick Ruz, Sarah Khan, Sneha Sharma, Alexa Meara, Syed Mahmood, Stephanie Feldman, Eric H YangSee the full list of authors
21 February 2024
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trialShengxiang Ren, Xicheng Wang, Bao-Hui Han, Yueyin Pan, Jun Zhao, Yufeng Cheng, Sheng Hu, Tianshu Liu, Yalun Li, Ying Cheng, Jifeng Feng, Shanyong Yi, Shanzhi Gu, Shegan Gao, Yongzhong LuoSee the full list of authors
21 February 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trialDavid P. Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, Manuel Cobo, Stéphanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Niels Reinmuth, Eduardo Richardet, Ying Cheng, Hideaki Mizutani, Enriqueta Felip, Bogdan Zurawski, Aurelia Alexandru, Luis Paz-AresSee the full list of authors
12 February 2024
Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancerShogo Takei, Yosuke Tanaka, Yi-Tzu Lin, Shohei Koyama, Shota Fukuoka, Hiroki Hara, Yoshiaki Nakamura, Yasutoshi Kuboki, Daisuke Kotani, Takashi Kojima, Hideaki Bando, Saori Mishima, Toshihide Ueno, Shinya Kojima, Masashi WakabayashiSee the full list of authors
8 February 2024
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)Margaret Callahan, Asim Amin, Frederic J Kaye, Michael A Morse, Matthew H Taylor, Katriina J Peltola, Padmanee Sharma, Eileen M O'Reilly, Stephanie Meadows Shropshire, Shaun O'Brien, Marina Tschaika, Dung T Le
5 February 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumorsSandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, Ding Wang, Jarushka Naidoo, Nathan E Standifer, Doug C Palmer, Lin-Yang Cheng, Panagiotis Kourtesis, Maria L Ascierto, Mayukh Das, Jennifer R Diamond, Matthew D Hellmann, Benedito A Carneiro
2 February 2024